Hazard

Sterility recalls

2,383 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total: 2,383
Critical: 1
Severe: 2,113
Most recent: 2026-08-26

Of the 2,383 sterility recalls we have scored against our rubric, 1 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 2,113 (89%) are Severe.

Which agencies issued them

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all sterility recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

451–475 of 2383

SevereFDA (Drugs)·D-1752-2019·2019-08-21
Infusion Options Recalls Bevacizumab Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling various Bevacizumab infusion bags in New York due to a lack of assurance of sterility.
Product
BEVACIZUMAB 784 MG / 100 ML NS IVPB; BEVACIZUMAB 350 MG/100 ml NS IVPB; BEVACIZUMAB 425 MG/ 100 ml NS IVPB; BEVACIZUMAB 420 MG/100 ml 0.9% NACL IVPB; BEVACIZUMAB 556 mg/100 ml NS IVPB BEVACIZUMAB 330 MG / 100 ML NS IVPB; BEVACIZUMAB 790 MG / 100 ML NS IVPB; BEVACIZUMAB 470 MG /
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1810-2019·2019-08-21
Infusion Options Recalls Rituximab Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling specific Rituximab infusion bags in New York due to a lack of assurance of sterility.
Product
RITUXIMAB 575 MG / 250 ml 0.9% NACL IVPB; RITUXIMAB 675 MG / 250 ml 0.9% NACL IVPB; RITUXIMAB 1000 MG / 1000 ml NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1772-2019·2019-08-21
Infusion Options Recalls Durvalumab Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling Durvalumab infusions in New York due to a lack of assurance of sterility.
Product
Durvalumab 651 mg/ 250 ml NS IVPB; Durvalumab 650 mg/ 250 ml NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1755-2019·2019-08-21
Infusion Options Recalls Calcium Glucunate IV Bags Due to Sterility Concerns
Infusion Options, Inc. is recalling Calcium Glucunate 1 gm/100 mL IV bags in New York due to a lack of assurance of sterility.
Product
CALCIUM GLUCONATE 1 GM /100 ML NACL 0.9% IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1749-2019·2019-08-21
Atezolizumab Infusion Recalled for Lack of Sterility Assurance
Infusion Options, Inc. is recalling Atezolizumab 1200 mg/250 mL in New York due to a lack of assurance of sterility.
Product
ATEZOLIZUMAB 1200 MG / 250 ML 0.9% NACL, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1778-2019·2019-08-21
Infusion Options Recalls FOSAPREPITANT Due to Sterility Assurance Concerns
Infusion Options, Inc. is recalling FOSAPREPITANT 150 mg/150 ml NS IVPB in New York due to a lack of assurance of sterility.
Product
FOSAPREPITANT 150 mg/150 ml NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1765-2019·2019-08-21
Infusion Options Recalls DARZALEX Infusion Bags Due to Sterility Concerns
Infusion Options, Inc. is recalling DARZALEX 1008 mg / 500 mL IV infusion bags in New York due to a lack of assurance of sterility.
Product
DARZALEX 1008 MG / 500 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1746-2019·2019-08-21
Adcetris IV Infusion Recalled for Lack of Sterility Assurance
Infusion Options, Inc. is recalling Adcetris 96 mg/100 mL IV infusion bags due to a lack of assurance of sterility. The product was distributed in New York.
Product
Adcetris 96 MG/100 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1817-2019·2019-08-21
Infusion Options Recalls Vinblastine Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling Vinblastine infusions in New York due to a lack of assurance of sterility.
Product
VINBLASTINE 10.9 MG / 100 ML D5W IVPB; VINBLASTINE 10.8 MG / 100 ML D5W IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
HighFDA (Drugs)·D-1815-2019·2019-08-21
Infusion Options Recalls Trastuzumab Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling multiple Trastuzumab infusion bags in New York due to a lack of assurance of sterility.
Product
TRASTUZUMAB 427 MG / 250 ml NS IVPB; TRASTUZUMAB 531 MG / 250 ML NS IVPB; TRASTUZUMAB 276 MG / 250 ML NS IVPB; TRASTUZUMAB 360 MG / 250 ML NS IVPB; TRASTUZUMAB 757 MG / 250 ML NS IVPB TRASTUZUMAB 450 MG / 250 ML NS IVPB; TRASTUZUMAB 120 MG / 250 ML NS IVPB; TRASTUZUMAB 164 MG /
Category
Drug
Distribution
1 state
HighFDA (Drugs)·D-1751-2019·2019-08-21
Infusion Options Recalls Azacitidine Syringes Due to Sterility Concerns
Infusion Options, Inc. is recalling Azacitidine syringes in New York due to a lack of assurance of sterility.
Product
AZACITIDINE 125 MG / 5 ML SUB-Q SYRINGE; AZACITIDINE 75 MG (3 ML) SYRINGE, AZACITIDINE 135 MG / 5.4 ML SUB-Q SYRINGE, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
HighFDA (Drugs)·D-1769-2019·2019-08-21
Infusion Options Recalls Docetaxel Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling various Docetaxel infusion bags in New York due to a lack of assurance of sterility.
Product
DOCETAXEL 60 MG / 250 ml D5W IVPB; DOCETAXEL 71 MG/ 250 ML NS IVPB; DOCETAXEL 155 MG/ 250 ml NS IVPB; DOCETAXEL 110 mg / 250 ml NS IVPB; DOCETAXEL 150 MG / 250 ml NS IVPB; DOCETAXEL 137 mg / 250 ml 0.9% NACL IVPB; DOCETAXEL 130 MG/ 250 ml NS IVPB; DOCETAXEL 140 MG/ 250 ml NS IVPB
Category
Drug
Distribution
1 state
HighFDA (Drugs)·D-1764-2019·2019-08-21
DARATUMUMAB infusion products recalled due to lack of assurance of sterility
The FDA is recalling DARATUMUMAB infusion solutions because sterility cannot be assured, creating a potential infection risk.
Product
DARATUMUMAB 904 MG QS 500 ML NS IVPB; DARATUMUMAB 668 MG QS 1000 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Category
Drug
Distribution
1 state
HighFDA (Drugs)·D-1761-2019·2019-08-21
Infusion Options Recalls Cyclophosphamide Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling various Cyclophosphamide infusion products in New York due to a lack of assurance of sterility.
Product
Cyclophosphamide 840 MG / 250 ML NS IVPB; Cyclophosphamide 1112 MG / 250 ML NS IVPB; Cyclophosphamide 1248 MG / 50 ML NS IVPB; Cyclophosphamide 1125 MG / 100 ML NS IVPB; Cyclophosphamide 1000 MG / 500 ML NS IVPB; Cyclophosphamide 1400 MG / 100 ML NS IVPB Cyclophosphamide 1056 MG
Category
Drug
Distribution
1 state
HighFDA (Drugs)·D-1783-2019·2019-08-21
Infusion Options Recalls HERCEPTIN Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling HERCEPTIN infusion bags in New York due to a lack of assurance of sterility.
Product
HERCEPTIN 400 MG / 250 ML NS IVPB; HERCEPTIN 340 MG /250 ml 0.9% NACL IVPB; HERCEPTIN 553 MG / 250 ml NS IVPB; HERCEPTIN 305 MG / 250 ml NS IVPB; HERCEPTIN 526 MG / 250 ML NS IVPB; HERCEPTIN 162 MG / 250 ML NS IVPB; HERCEPTIN 354 MG/ 250 ml 0.9% NACL IVPB; HERCEPTIN 440 MG / 250
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1679-2019·2019-08-14
RXQ Compounding Recalls Methylcobalamin Injectable Due to Sterility Concerns
RXQ Compounding LLC is recalling Methylcobalamin 10 mg/mL injectable vials because the product lacks assurance of sterility.
Product
METHYLCOBALAMIN (PFV) 10 MG/ML INJECTABLE, 10 ML per vial, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0902-10
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1704-2019·2019-08-14
RXQ Compounding Recalls Sodium Bicarbonate Injection Due to Sterility Concerns
RXQ Compounding LLC is recalling Sodium Bicarbonate 8.4% Injection due to a lack of assurance of sterility. The product is distributed nationwide.
Product
SODIUM BICARBONATE 8.4% (1 MEQ/ML) INJ SOLN (PFV), 50 ML PER VIAL, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0957-50
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1706-2019·2019-08-14
RXQ Compounding Recalls SOD-PHOS Injection Due to Sterility Concerns
RXQ Compounding LLC is recalling SOD-PHOS injection vials because the product lacks assurance of sterility. The recall covers all lots within their expiry dates.
Product
SOD-PHOS (PHOS 3MMOL/ML-SOD 4MEQ/ML) PFV INJ SOLN, 10 ML PER VIAL, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0905-10
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1705-2019·2019-08-14
RXQ Compounding Recalls Lidocaine Syringes Due to Sterility Concerns
RXQ Compounding LLC is recalling Lidocaine 0.75%/Epinephrine 0.025% syringes because the FDA determined there is a lack of assurance of sterility.
Product
LIDOCAINE 0.75%/Epinephrine 0.025%/BSS 0.56ML SYR, 1 ML PER Syringe, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0919-01
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1703-2019·2019-08-14
RXQ Compounding Recalls Phenylephrine and Lidocaine Ophthalmic Solution
RXQ Compounding LLC is recalling ophthalmic solution vials due to a lack of assurance of sterility. The product is distributed nationwide.
Product
RXQ CAIN (PHENYLEP 1.5%/ LIDO 1% OPHTH SOL (PF), 1 ML PER VIAL, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0918-01
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1676-2019·2019-08-14
RXQ Compounding Recalls Manganese Sulfate Injection Due to Sterility Concerns
RXQ Compounding LLC is recalling Manganese Sulfate Monohydrate Injection because the product lacks assurance of sterility. The recall covers all lots within expiry distributed nationwide.
Product
MANGANESE SULFATE MONOHYDRATE (PFV) 0.1MG/ML INJ, 10 ML per syringe, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0952-10
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1716-2019·2019-08-14
RXQ Compounding Recalls Vitamin B Complex 100 Due to Sterility Concerns
RXQ Compounding LLC is recalling Vitamin B Complex 100 (MDV) vials because the product lacks assurance of sterility.
Product
VITAMIN B COMPLEX 100 (MDV), 30 ML per Vial, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC 70731-0976-30
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1719-2019·2019-08-14
RXQ Compounding Recalls Zinc Sulfate Injection Due to Sterility Concerns
RXQ Compounding LLC is recalling Zinc Sulfate 1mg/mL Injection Solution because the product lacks assurance of sterility.
Product
ZINC SULFATE 1MG/ML INJECTION SOLUTION, 30ML per VIAL, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC 70731-0152-30
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1638-2019·2019-08-14
RXQ Compounding Recalls Buffered Lidocaine Injection Due to Sterility Concerns
RXQ Compounding LLC is recalling Buffered Lidocaine 1%+Epi 1:100,000 Injection Solution because the product lacks assurance of sterility.
Product
BUFFERED LIDOCAINE 1%+EPI 1:100,000 INJ SOL, [3ML NDC: 70731-0137-03 and 30ML NDC: 70731-0137-30] per syringe, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0137-03
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1710-2019·2019-08-14
RXQ Compounding Recalls Thiamine HCL Injection Due to Sterility Concerns
RXQ Compounding LLC is recalling Thiamine HCL 100mg/mL Injection because the product lacks assurance of sterility. The recall covers all lots within expiry distributed nationwide.
Product
THIAMINE HCL 100MG/ML (MDV) INJECTION, 10 ML per Vial, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC 70731-0950-10
Category
Drug
Distribution
Distributed nationwide